Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2020 · $11,154,495 — Saint Louis University (SLU) seeks to expand its service to the Vaccine and Treatment Evaluation Unit (VTEU) network providing resources and expertise to help the network achieve its objectives of evaluating vaccines, preventive biologics, therapeutics and diagnostics for infectious diseases. Dr. Da…
Mark A Jutila · MONTANA STATE UNIVERSITY - BOZEMAN · 2019 · $180,000 — Brucellosis is a zoonotic infection caused by Brucella species. Two species, B. abortus and B. melitensis, are select agents and considered potential bioweapons, and there are no approved vaccines for use in humans. Approved vaccines do exist for livestock; however, they are only 60-70% effective, a…
ASHOK K CHOPRA · UNIVERSITY OF TEXAS MED BR GALVESTON · 2019 · $161,477 — This is a third competitive renewal of our very successful Biodefense Training Program (BTP) for predoctoral students; first funded in 2004, prior to the building of the Galveston National Laboratory (GNL) in 2008. Since then, there has been an explosive growth of research at UTMB on biodefense-rela…
Karl E Klose · UNIVERSITY OF TEXAS SAN ANTONIO · 2019 · $223,250 — Francisella tularensis (Ft), Yersinia pestis (Yp), and Bacillus anthracis (Ba) are considered Category A bioweapons due to ease of transmission, low infectious dose and high mortality associated with pneumonic forms of disease, and the fact that all have been intensively studied and developed in bio…
John Beutler · DIVISION OF BASIC SCIENCES - NCI · 2019 · $630,232 — We established MTAs with three of the four NIGMS-funded Chemical Methodologies & Library Developments (CMLD) (Boston University, University of Kansas, and University of Pittsburgh). These three centers alone have provided over 15,000 samples of known structure. Each CMLD has a distinct approach to l…
Jose Alfonso Rodriguez · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2019 · $234,000 — PROJECT SUMMARY New World Hemorrhagic Fever (NWHF) mammarenaviruses are category A pathogens that pose a grave threat to humans due their high infectivity, mortality between 15-30% when untreated, and our lack of therapeutic options. A subgroup of NWHF mammarenaviruses include the clade B pathogens …
Slobodan Paessler · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $626,423 — PROJECT ABSTRACT/SUMMARY The viruses belonging to the family Arenaviridae contain several causative agents of hemorrhagic fever in humans. For instance, Lassa virus causes Lassa fever, which is a major public health threat in endemic regions of West Africa. Junin virus, Machupo virus, Guanarito viru…
Daniel S Chertow · CLINICAL CENTER · 2024 — Project 1: We previously developed a NHP ICU model in healthy (uninfected) NHPs. We have extended this model to included supportive care of animals infected with E.coli or K. pneumoniae. Among K. pneumoniae infected animals, we have completed a bacterial dose-response study. The manuscript is has b…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $215,675
Thomas William Geisbert · UNIVERSITY OF WASHINGTON · 2024 · $5,867,641 — PROJECT SUMMARY – CORE D: ANIMAL MODELS AND VACCINE EVALUATION Among viruses that cause disease in humans viral zoonoses within the family Paramyxoviridae and order Bunyavirales contain pathogens that cause significant lethality. Importantly, within the Paramyxovirdae the zoonotic henipavirus Hendra…
Thomas William Geisbert · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $4,640,498 — PROJECT SUMMARY/ABSTRACT – Core E (Animal Model Development and Preclinical Evaluation) Among viruses that cause disease in humans, viral zoonoses within the family Paramyxoviridae and order Bunyavirales contain pathogens that cause significant lethality. Importantly, the Arenaviridae and Nairovirid…
BLANCA I RESTREPO · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $887,558 — ABSTRACT Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), is a leading infectious disease and cause of death worldwide. The growing burden of drug-resistant (DR)-TB is complicating TB treatment. Early diagnosis of TB with drug susceptibility testing (DST) is critical for successful tr…
Harris R Perlman · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $799,322 — Project Summary/ Abstract The aim of the Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core Facility is to provide analysis and cell sorting to enhance scientific interaction and productivity within Northwestern University’s research community. This is accomplished by allowing access to…
Ryan P Bennett · OYAGEN, INC. · 2024 · $298,000 — PROJECT SUMMARY This R43 proposal answers the call of the RFA PA-22-176 for assay development and chemical probe screening by addressing the unmet need for development of antiviral treatments for Ebola patients through an innovative high-content small molecule screen for antagonists of the Ebola VP4…
Gaya K. Amarasinghe · WASHINGTON UNIVERSITY · 2024 · $3,374,001 — Overall Project Summary/Abstract: Molecular mechanisms of filoviral-host interactions The family Filoviridae, which includes Ebola virus (EBOV) and Marburg virus (MARV), are zoonotic pathogens that cause outbreaks of severe human disease and require biosafety level 4 (BSL4) containment for study. Re…
Gregg A Dean · COLORADO STATE UNIVERSITY · 2024 · $466,724 — Contact PD/PI: Dean, Gregg A. Infectious Disease Research and Response Training Program (IDRRTP) The Infectious Disease Research and Response Network (IDRRN) was established in 2016 and has been recognized as a Program of Research and Scholarly Excellence (PRSE) at Colorado State University. The IDR…
ROBERT A DAVEY · WASHINGTON UNIVERSITY · 2024 · $357,893 — Core C – Project Summary/Abstract Core C provides support for high biocontainment work to Research Projects 1 (RP01), RP02, RP03 and Core B. Work is prioritized through Core A. Core personnel bring unique expertise in molecular biology, cell biology and animal disease modeling for Ebola and Marburg …
JILL E HUTCHCROFT · PURDUE UNIVERSITY · 2024 · $82,914 — Flow Cytometry Shared Resource (FC-SR) Project Summary The Purdue Flow Cytometry Shared Resource (FC-SR) provides advanced cell and particle analysis, cell sorting and single cell genomic capabilities to members of the Purdue University Center for Cancer Research (PCCR). The FC-SR has made major i…
Colleen B Jonsson · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2024 · $1,295,544 — PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety le…
RONALD B CORLEY · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $538,414 — Administrative Core Summary The NEIDL Administrative Core provides the leadership, organizational structure, and direction of an established management plan that sustains the resources and infrastructure of the NEIDL at the highest level. This enables us to meet our mandate as a member of NIAID’s na…